← Leaderboards
Shyamala Maheswaran
Massachusetts General Hospital
$4,911,288
Attributed
$10,464,399
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,464,399 · 4
By mechanism
R01$7,532,055 · 3
U01$2,932,344 · 1
Top collaborators
- Daniel A. Haber15 shared
- Mehmet Toner15 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Patricia K Donahoe$22,937,861
- Joel S Finkelstein$18,947,740
- Jose M Teixeira$9,923,155
- William F Crowley$27,565,527
- Christopher Houk$100,052
Others in their field
Top investigators on “Neoplastic Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Andrea Califano · Columbia University Health Sciences$22,374,316
- Wendell A Lim · University Of California, San Francisco$22,334,734
Research focus
Neoplastic CellResponseTumorCellsGeneticBiologicalBloodMicrofluidicsNeoplasm Circulating CellsPropertyNeoplasm MetastasisCancer CellMalignant NeoplasmsBreastMouse ModelDesignBlood CellsLesionComplexHourLeukapheresisCancer PatientBiomedical EngineeringCancer Therapy
Grant awards (25)
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells$647,628
R01 · FY2025 · CA
Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy$453,440
R01 · FY2025 · CA
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells$615,247
R01 · FY2024 · CA
Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy$430,769
R01 · FY2024 · CA
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells$634,675
R01 · FY2023 · CA
Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy$443,269
R01 · FY2023 · CA
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells$631,907
R01 · FY2022 · CA
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation$594,889
U01 · FY2022 · CA
Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy$443,269
R01 · FY2022 · CA
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells$644,804
R01 · FY2021 · CA
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation$534,584
U01 · FY2021 · CA
Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsy$452,315
R01 · FY2021 · CA
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation$607,028
U01 · FY2020 · CA
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation$588,815
U01 · FY2019 · CA
Metastasis and biophysics of clusters of circulating tumor cells in the microcirculation$607,028
U01 · FY2018 · CA
MIS mediated inhibition of breast cancer cell growth$275,186
R01 · FY2008 · CA · contact PI
MIS mediated inhibition of breast cancer cell growth$275,186
R01 · FY2007 · CA · contact PI
MIS mediated inhibition of breast cancer cell growth$283,405
R01 · FY2006 · CA · contact PI
MIS mediated inhibition of breast cancer cell growth$290,225
R01 · FY2005 · CA
MIS mediated inhibition of breast cancer cell growth$289,950
R01 · FY2004 · CA
MIS mediated inhibition of breast cell growth$20,011
R01 · FY2004 · CA
MIS mediated inhibition of breast cell growth$226,980
R01 · FY2003 · CA
MIS mediated inhibition of breast cell growth$25,085
R01 · FY2003 · CA
MIS mediated inhibition of breast cell growth$226,980
R01 · FY2002 · CA
MIS mediated inhibition of breast cell growth$221,724
R01 · FY2001 · CA